Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund has shown a recent increase in trading volume and share count, despite a negative return since its inception [1] Group 1: Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF (159297) rose by 2.59% on October 15, with a trading volume of 85.1141 million yuan [1] - The fund's share count increased by 34 million, bringing the total to 784 million shares [1] - The latest net asset value is calculated at 709 million yuan [1] Group 2: Benchmark and Management - The fund's performance benchmark is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] Group 3: Historical Returns - Since its establishment on September 12, 2025, the fund has recorded a return of -9.56% [1] - Over the past month, the fund's return has been -9.63% [1]
10月15日港股通创新药ETF南方（159297）份额增加3400.00万份
Xin Lang Cai Jing·2025-10-16 01:12